Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
- Category: Antibodies
- Published on Monday, 10 June 2019 16:39
- Hits: 491
REWIND data showed a consistent effect in people with and without established cardiovascular disease
INDIANAPOLIS, IN, USA I June 9, 2019 I Detailed results from REWIND, the Trulicity® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular events (MACE), a composite endpoint of non-fatal myocardial infarction (heart attack), non-fatal stroke or CV death. REWIND data showed a consistent MACE 3 effect in people with and without established CV disease. The CV risk reduction was sustained throughout the trial's duration.1 The highly anticipated data for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity were presented during a symposium today at the American Diabetes Association's® 79th Scientific Sessions® and simultaneously published in The Lancet.1
REWIND is the longest cardiovascular outcome trial in the GLP-1 receptor agonist class (median 5.4 years) and consisted primarily of people without established CV disease. While all participants had CV risk factors, only 31 percent of study participants had established CV disease. The study also had one of the lowest median baseline A1Cs of any diabetes CV outcome trial to date (7.2 percent) and had a balanced ratio of women (46.3 percent) to men (53.7 percent). This patient population is more representative of people with type 2 diabetes typically seen in clinical practice.2
"Dulaglutide is the first type 2 diabetes medicine to significantly reduce major adverse cardiovascular events (MACE 3) in a study population where the majority of participants had CV risk factors without established CV disease," said Hertzel Gerstein, M.D., MSc, FRCPC, professor of medicine and deputy director of the Population Health Institute at McMaster University and Hamilton Health Sciences, and REWIND study chair. "REWIND showed that adding dulaglutide to the therapeutic regimen of type 2 diabetes will benefit a broad range of people."
REWIND compared the effect of Trulicity 1.5 mg to placebo, both in addition to standard of care, on the risk of MACE 3 in 9,901 adults with type 2 diabetes. The risk reduction shown by Trulicity for the overall study (HR=0.88, 95% CI: 0.79-0.99) was consistent across subgroups, including: 1
- established cardiovascular disease: HR=0.87, 95% CI: 0.74-1.02;
- no established cardiovascular disease: HR=0.87, 95% CI: 0.74-1.02;
- baseline A1C greater than or equal to 7.2 percent: HR=0.86, 95% CI: 0.74-1.00;
- baseline A1C less than 7.2 percent: HR=0.90, 95% CI: 0.76-1.06;
- women: HR=0.85, 95% CI: 0.71-1.02; and
- men: HR=0.90, 95% CI: 0.79-1.04.
All three components contributed to the significant reduction Trulicity provided in MACE 3, including CV death (HR=0.91, 95% CI: 0.78-1.06), non-fatal heart attack (HR=0.96, 95% CI: 0.79-1.16) and non-fatal stroke (HR=0.76, 95% CI: 0.61-0.95). Trulicity further showed reductions in composite microvascular outcomes (HR=0.87, 95% CI: 0.79-0.95), characterized by fewer composite renal outcomes.1 Analysis of the renal outcomes suggests long-term Trulicity use was associated with reduced progression of renal disease in people with type 2 diabetes.3
In addition to the long-term follow-up assessing CV outcomes, REWIND provides additional evidence of Trulicity's efficacy in treating diabetes. Trulicity reduced A1C across the study from a median baseline of 7.2 percent compared to placebo (A1C: -0.46 percent [Trulicity], +0.16 percent [placebo]; Weight: -2.95 kg [Trulicity], -1.49 kg [placebo]). 1
Trulicity's safety profile was consistent with the GLP-1 receptor agonist class. The most common adverse events leading to the discontinuation of Trulicity were gastrointestinal events.1
"Trulicity is already well-known for helping people with type 2 diabetes reach their blood glucose goals with a weekly dose," said Brad Woodward, M.D., global development leader, Incretins, Lilly. "Detailed results from our landmark REWIND trial demonstrate a cardiovascular benefit in a more representative population of people with type 2 diabetes. These data suggest Trulicity can help physicians and people with type 2 diabetes better manage blood glucose and cardiovascular risk over the long-term."
The REWIND results have been submitted to regulatory authorities in the U.S. and Europe for review.
Lilly will host an investor call Monday, June 10, at 10:00 a.m. EDT (7:00 a.m. PDT) to discuss the company's presentations at the American Diabetes Association's 79th Scientific Sessions.
About the REWIND Study
REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) was a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the effect of Trulicity 1.5 mg, a weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA), compared to placebo, both added to standard of care (according to local standard of care guidelines), on cardiovascular (CV) events in adults with type 2 diabetes. The primary CV outcome was the first occurrence of MACE (the composite of CV death or non-fatal myocardial infarction or non-fatal stroke). Secondary outcomes include each component of the primary composite CV outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. The 9,901 participants from 24 countries had a mean duration of diabetes of 10.5 years and a median baseline A1C of 7.2 percent. While all participants had CV risk factors, only 31 percent of the study participants had established CV disease. Prior (or established) cardiovascular disease in REWIND was defined as prior myocardial infarction, prior ischemic stroke, prior unstable angina, prior revascularization (coronary, carotid, or peripheral), prior hospitalization for ischemia-related events (unstable angina or myocardial ischemia on imaging, or need for percutaneous coronary intervention), or prior documented myocardial ischemia.
The REWIND trial's international scope, high proportion of women, high proportion of people without established cardiovascular disease and inclusion of participants with a lower mean baseline A1C suggest that the findings will be directly relevant to the typical type 2 diabetes patient seen in general practice throughout the world.
Indication and Limitations of Use for Trulicity®
Trulicity is a once-weekly injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It should be used along with diet and exercise. Trulicity is not recommended as the first medication to treat diabetes. It has not been studied in people who have had inflammation of the pancreas (pancreatitis). Trulicity should not be used by people with type 1 diabetes, people with diabetic ketoacidosis, or people with a history of severe gastrointestinal (GI) disease. It is not a substitute for insulin. It has not been studied in children under 18 years of age.
Approximately 30 million Americans4 and an estimated 425 million adults worldwide have diabetes.5 Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone.4 Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes. We offer a wide range of therapies and a continued determination to provide real solutions—from medicines and technologies to support programs and more. For the latest updates, visit http://www.lillydiabetes.com/or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY
Trulicity® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
|1.||Gerstein HC, Colhoun HM, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019. S0140-6736(19)31149-3. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext.|
|2.||Boye KS, Riddle MC, Gerstein HC, et al. Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States. Diabetes Obes Metab 2019.|
|3.||Gerstein HC, Colhoun HM, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. 2019. S0140-6736(19)31150. Retrieved from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31150-X/fulltext.|
|4.||Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017.|
|5.||International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org.|
SOURCE: Eli Lilly